• Evotec entered a research collaboration with Plectonic Biotech to develop next-generation T-cell-engaging immunotherapies for solid tumors.
• Work will combine Evotec’s BiTco CD2 costimulatory bispecific platform with Plectonic’s logic-gated LOGIBODY DNA-protein technology.
• Program targets improved tumor selectivity, stronger T-cell activation, reduced off-tumor activity, improved potency in solid tumors.
• Parties plan to generate preclinical proof-of-concept data to evaluate the combined approach.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evotec SE published the original content used to generate this news brief via EQS News (Ref. ID: corporate_2390500_en) on September 02, 2026, and is solely responsible for the information contained therein.